The association of three vaccination doses with reduced gastrointestinal symptoms after severe acute respiratory syndrome coronavirus 2 infections in patients with inflammatory bowel disease.

Publication date: Jan 28, 2024

The protective efficacy of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination against the new-onset gastrointestinal (GI) symptoms following COVID-19 infection is critical among patients with inflammatory bowel disease (IBD); however, the optimal protective vaccine dose remains unknown. Therefore, this study aimed to clarify whether there is a correlation between SARS-CoV-2 vaccinations and GI symptoms following Omicron infection in patients with IBD. We conducted a multicenter cross-sectional study of IBD patients among three tertiary hospitals in eastern China. Professional physicians collected all data using online questionnaires. The patients were stratified into four groups: patients who were unvaccinated and patients who received one, two, or three vaccination doses. The primary outcome was the presence of any new-onset GI symptoms after SARS-CoV-2 infection before a negative SARS-CoV-2 nucleic acid test or a negative self-testing for antigens. In total, 536 patients with IBD (175 unvaccinated, 31 vaccinated, 166 vaccinated with two doses, and 164 vaccinated with three doses) reported having COVID-19 infection. Compared with the unvaccinated, the three vaccination doses group was associated with reduced GI symptoms after infection (adjusted odds ratio = 0. 56, 95% confidence interval 0. 34-0. 90, P < 0. 05). Reduced diarrhea (adjusted odds ratio = 0. 54, 95% confidence interval 0. 31-0. 92, P < 0. 05) and nausea or vomiting (adjusted odds ratio = 0. 45, 95% confidence interval 0. 21-0. 92, P < 0. 05) were observed in the three vaccination doses group compared with the unvaccinated group. In conclusion, in the 536 patients with IBD who reported COVID-19 infection, we found that the three vaccination doses, but not the one or two doses group, were associated with reduced GI symptoms after infection compared with the unvaccinated group.

Open Access PDF

Concepts Keywords
China activity
Coronavirus duration
Gastrointestinal gastrointestinal symptoms
Hospitals inflammatory bowel disease
Professional SARS-CoV-2 vaccine
three vaccination doses


Type Source Name
disease VO vaccination
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH infections
disease MESH inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
disease MESH COVID-19
disease IDO infection
disease VO vaccine dose
disease VO unvaccinated
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccinated
drug DRUGBANK Coenzyme M
disease VO vaccine
disease MESH ulcerative colitis
disease MESH etiology
disease MESH Viral infections
disease MESH autoimmune diseases
disease MESH anorexia
disease MESH hematochezia
disease VO population
disease VO protocol
disease VO dose
disease VO monthly
disease VO inactivated vaccine
disease VO protection efficacy
disease VO organization
disease VO immunization
disease IDO symptom
disease MESH comorbidity
drug DRUGBANK Acetylsalicylic acid
disease MESH cerebrovascular disease
disease MESH lung diseases
disease MESH liver disease
disease MESH kidney disease
disease MESH tumors
disease MESH pneumonia
disease VO vaccination dose
drug DRUGBANK Methotrexate
disease MESH Crohn’s disease
drug DRUGBANK Azathioprine

Original Article

(Visited 1 times, 1 visits today)